Keywords
glaucoma, outflow, surgery, trabectome, ab interno trabeculectomy, disease index
This article is included in the Eye Health gateway.
glaucoma, outflow, surgery, trabectome, ab interno trabeculectomy, disease index
Due to an increasing human lifespan, chronic diseases that manifest later in life, such as glaucoma and cataracts, have an increasing incidence and often occur in the same individuals1. In addition, medications used to treat glaucoma2 or interventions to reduce intraocular pressure (IOP)3 can cause cataracts or accelerate their occurrence. Traditional glaucoma surgery consists of trabeculectomy or tube shunt implantation, both of which have a relatively high frequency of serious complications. Ab interno trabeculectomy with the trabectome, a plasma surgical modality that ionizes and aspirates the trabecular meshwork with minimal energy transfer to surrounding tissues, was first introduced in 20044 and is considered a more mature microincisional glaucoma surgery. Trabectome surgery, similar to other surgeries in this family, has a favorable safety profile5 but is often only performed in ocular hypertension or mild glaucoma stages6.
The primary outflow resistance in glaucoma is the trabecular meshwork7. However, more recent insight has also demonstrated a significant contribution to elevated pressure in glaucoma by an outflow resistance that is downstream of the trabecular meshwork8–10. According to the Goldmann equation, the limiting factor in pressure reduction from ab interno trabeculectomy with the trabectome is this residual resistance and the pressure of the episcleral veins11, and this may vary depending on glaucoma type12 and severity. Glaucoma severity can be described by visual field13, optic nerve damage, and also by the number of medications needed to achieve a target IOP14.
We recently examined the amount of IOP reduction that is due to phacoemulsification at the time of trabectome surgery and found this to be relatively clinically insignificant9. We also noted that trabectome surgery performed after failed trabeculectomy caused patients with more advanced visual field damage to have on average a greater pressure reduction despite similar medications10. In the current study we have consequently combined data of trabectome and phaco-trabectome surgery patients and stratified them by a glaucoma severity index. By combining both trabectome and phaco-trabectome surgery data, a more complete picture can be obtained to guide surgeons on whether ab interno trabeculectomy may be an appropriate primary intervention.
This retrospective analysis was approved (PRO14100026) by the Institutional Review Board of the University of Pittsburgh in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act. Because of the retrospective nature, no consent was required. Glaucoma patients who received trabectome with or without phacoemulsification were enrolled, except in the following circumstances: history of glaucoma surgery, any subsequent cataract or glaucoma surgery in the follow-up period, and short term followup (less than 12 months). Patients were divided into four groups (from mild to severe) according to a glaucoma index (GI), an indicator of glaucoma severity based on visual field, numbers of glaucoma medication, and preoperative IOP14. GI group 1 = mild, GI group 2 = moderate, GI group 3 = advanced, and GI4 = severe were defined based on glaucoma index scores of “≤4”, “4<GI≤8”, “8<GI≤16”, and “>16,” respectively. The main outcome measure was the reduction of IOP. Secondary outcome measures included reduction of medication and a Kaplan-Meier survival analysis. Baseline characteristics were analyzed by the Kruskal-Wallis and chisquare tests for continuous and categorical variables between GI groups, respectively. Univariate linear regression was performed first and those demographics found to be statistically significant were included into the multivariate regression analysis. Kaplan-Meier was used for survival-curve analyses. Surgical success was defined as IOP≤21 mmHg or at least 20% IOP reduction from baseline in any two consecutive visits after three months and no secondary glaucoma surgery. Log-rank test was used to compare survival distributions of GI groups.
A total of 1340 cases of glaucoma patients were enrolled in the study and most of them were primary open angle glaucoma (POAG). The distribution across glaucoma severity groups was relatively even in number and average ages (Table 1). There was a slight preponderance of female patients in the mild and moderate groups. The ethnicity of most patients was Caucasian followed by Asian. POAG and pseudoexfoliation glaucoma were the most common diagnoses. The cup disc ratio increased by glaucoma index group and more patients were phakic than pseudophakic. More patients in the higher GI groups had a trabectome surgery that was combined with cataract surgery. Patients with a higher GI group had a more profound IOP reduction (Figure 1). At one year, the mean IOP reduction was 3.57±5.01, 5.34±5.40, 7.75±7.40, 12.09±8.08 mmHg for GI group 1 to 4, respectively. This pressure decrease occurred already on day 1 and remained relatively stable (Figure 2). Similarly, patients with more severe glaucoma experienced a larger reduction in medications which were tapered more gradually (Figure 3). When we stratified the overall IOP reduction by glaucoma severity, patients with worse glaucoma had the largest decrease.
Glaucoma index (GI); GI1 Mild: GI≤4; GI2 Moderate: 4<GI≤8; GI3 Advanced: 8<GI≤16; GI4 Severe: GI>16.
More severe glaucoma was associated with a larger pressure reduction.
Patients with a higher group had the largest decrease (average and standard deviation).
Patients in the severe and advanced groups had the largest medication reduction (average and standard deviation).
In the univariate regression analysis, age was slightly negatively correlated with the amount of IOP reduction (Table 2) but this was not noted in the multivariate regression (Table 3) while male gender had a positive correlation in the univariate but not anymore in the multivariate regression. For patients in the higher GI group, the IOP reduction was 2.34±0.19 mmHg more than those in one level lower GI group while holding everything else constant. Hispanics experienced a pressure drop larger by 3.81±1.08 mmHg than other ethnicities as did patients with a diagnosis of pseudoexfoliation and steroid induced glaucoma (Table 3). IOP reduction was 2.91±0.56 and 3.86±0.81 mmHg more than in POAG patients. Interestingly, cataract surgery was associated with a slightly worse IOP reduction by 1.29+/-0.39 mmHg (Table 3).
Survival rate at 12 months was 93%, 84%, 82% and 74% for GI group 1 to 4 (Figure 4). Log-rank test indicated statistically significant differences between the GI groups and patients in the lower GI groups had a higher survival rate than those in higher GI groups.
The results of the current study are confirmatory of our prior study where we examined the impact of a glaucoma severity index on the results of trabectome surgery when done as a standalone procedure14. The larger number of patients involved here allowed discovery of additional factors. We included here phaco-trabectome patients, who have a different, mixed indication that often includes visually significant cataract as the primary motivator while presenting with a relatively stable glaucoma. We did so after demonstrating by a rigorous statistical matching method, coarsened exact matching15, that phacoemulsification does not contribute significantly to IOP reduction when done at the same time9 or in a surgery prior to trabectome surgery16.
The results of this study match established risk factors and findings from other studies. Steroid glaucoma and pseudoexfoliation often produce very high IOPs and the primary pathology is located in the trabecular meshwork. As a result, ablating the meshwork reduces intraocular pressure very effectively17.
In that study we found that a larger pressure reduction is achieved in more severe glaucoma consisting of a more advanced visual field damage, a higher pre-intervention IOP and more medications. We had previously found that cup disc ratio, Hispanic ethnicity and diagnosis of steroid-induced glaucoma are related to a larger IOP reduction14. In addition to steroid induced glaucoma, pseudoexfoliation glaucoma confers a larger IOP reduction in the present study. Although phacoemulsification was negatively correlated with IOP reduction in this analysis, something that has been described for combined traditional trabeculectomy18,19, it is important to recall that this study was not designed to formally compare outcomes of combined versus trabectome-alone as we have done before9. The number of patients analyzed here is significantly higher than in the two separate studies but we note similar results in the regression analysis allowing to discover additional factors.
The Goldmann equation describes that the limiting factor to IOP reduction after removal of the trabecular meshwork, the substrate of the main outflow resistance, is the episcleral venous pressure and uveoscleral outflow11. The data presented here indicate that that this is mostly true also for more advanced glaucoma and consistent with two prior studies that demonstrated that significant conventional outflow can be recovered even after failed tube shunts20 and after failed trabeculectomy10. Small differences of the eventually achieved pressures could be explained by an episcleral venous pressures that is higher in glaucoma12. Overall, the data presented here suggest that ab interno trabeculectomy might be an appropriate surgery to attempt to control more than mild glaucoma.
The raw datasets could not be made available because the data could not be sufficiently anonymised to protect patient confidentiality. No individuals other than the investigators or research staff involved in the conduct of this research study and authorized representatives of the University Research Conduct and Compliance Office (RCCO) are permitted access to research data or documents (including medical record information) associated with the conduct of this research study. Institutional IRB rules are available on the following University of Pittsburgh OSIRIS website: http://www.osiris.pitt.edu/osiris. The approval permit number for this study is PRO14100026.
YD, PR, RTL and NAL acquired and analyzed the data, all authors participated in writing and reviewing the manuscript, NAL provided funding.
NAL has received honoraria for trabectome wet labs and lectures from Neomedix Corp.
This study was funded by the Eye and Ear Foundation of Pittsburgh.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: Dr Sarkisian is a consultant to New World Medical, Sight Sciences, Beaver Vistec International, Glaukos, Alcon, Aeon Astron, and InnFocus. He has received research funding from Glaukos, Transcend, and Aeon Astron.
References
1. Loewen RT, Roy P, Parikh HA, Dang Y, et al.: Impact of a Glaucoma Severity Index on Results of Trabectome Surgery: Larger Pressure Reduction in More Severe Glaucoma.PLoS One. 2016; 11 (3): e0151926 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 27 Jun 16 |
read | read | |
Version 1 27 Apr 16 |
read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)